Entrada Therapeutics to release Cohort 1 topline data for ENTR-601-44 DMD trial May 7

Entrada Therapeutics Inc

Entrada Therapeutics Inc

TRDA

0.00
  • Entrada Therapeutics scheduled release of topline Cohort 1 results from Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 in Duchenne muscular dystrophy for May 7, 2026.
  • Data readout will cover Cohort 1 participants in double-blind, placebo-controlled, multiple-ascending-dose portion of trial, setting near-term direction for program’s clinical path.
  • Investor webcast and conference call set for 8:30 a.m. ET on May 7, 2026 to discuss results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.